Iqbal S. Grewal
Keine laufenden Positionen mehr
Profil
Iqbal S.
Grewal worked as a Senior Scientist in the Immunology Department at Genentech, Inc. and as a Vice President in Preclinical Therapeutics at Seagen Inc. Grewal holds a graduate degree from the University of Aberdeen, a doctorate from the University of California, Los Angeles, and an undergraduate degree from Panjab University Chandigarh.
Ehemalige bekannte Positionen von Iqbal S. Grewal
| Unternehmen | Position | Ende |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Ausbildung von Iqbal S. Grewal
| University of California, Los Angeles | Doctorate Degree |
| University of Aberdeen | Graduate Degree |
| Panjab University Chandigarh | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
